Hydase (hyaluronidase injection, USP)

Published Online: Sunday, January 1, 2006

PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit www.primapharm.net.

Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues